302 related articles for article (PubMed ID: 21328340)
41. Temozolomide in malignant gliomas: current use and future targets.
Villano JL; Seery TE; Bressler LR
Cancer Chemother Pharmacol; 2009 Sep; 64(4):647-55. PubMed ID: 19543728
[TBL] [Abstract][Full Text] [Related]
42. Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Guan DG; Chen HM; Liao SF; Zhao TZ
Mol Med Rep; 2015 Nov; 12(5):7705-11. PubMed ID: 26459853
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
44. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
45. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
Yi GZ; Liu YW; Xiang W; Wang H; Chen ZY; Xie SD; Qi ST
J Neurol Sci; 2016 Aug; 367():101-6. PubMed ID: 27423571
[TBL] [Abstract][Full Text] [Related]
46. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
[TBL] [Abstract][Full Text] [Related]
47. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
Liu X; Wang L; Chen J; Ling Q; Wang H; Li S; Li L; Yang S; Xia M; Jing L
Mol Med Rep; 2015 Feb; 11(2):1516-22. PubMed ID: 25351348
[TBL] [Abstract][Full Text] [Related]
48. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.
Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C
Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882
[TBL] [Abstract][Full Text] [Related]
49. Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Alexiou GA; Gerogianni P; Vartholomatos E; Kyritsis AP
Cancer Invest; 2016 Nov; 34(10):489-495. PubMed ID: 27768402
[TBL] [Abstract][Full Text] [Related]
50. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
51. Honokiol enhances temozolomide-induced apoptotic insults to malignant glioma cells via an intrinsic mitochondrion-dependent pathway.
Chio CC; Tai YT; Mohanraj M; Liu SH; Yang ST; Chen RM
Phytomedicine; 2018 Oct; 49():41-51. PubMed ID: 30217261
[TBL] [Abstract][Full Text] [Related]
52. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
[TBL] [Abstract][Full Text] [Related]
53. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
Dai C; Zhang B; Liu X; Guo K; Ma S; Cai F; Yang Y; Yao Y; Feng M; Bao X; Deng K; Jiao Y; Wei Z; Junji W; Xing B; Lian W; Wang R
Int J Cancer; 2013 Oct; 133(8):1982-93. PubMed ID: 23564480
[TBL] [Abstract][Full Text] [Related]
54. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
55. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
56. Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells.
Liang P; Shi H; Zhu W; Gui Q; Xu Y; Meng J; Guo X; Gong Z; Chen H
Oncotarget; 2017 Jan; 8(5):7533-7539. PubMed ID: 27893419
[TBL] [Abstract][Full Text] [Related]
57. UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma.
Zhou K; Wang D; Du X; Feng X; Zhu X; Wang C
Acta Biochim Biophys Sin (Shanghai); 2024 Jun; 56(6):916-926. PubMed ID: 38634120
[TBL] [Abstract][Full Text] [Related]
58. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
[TBL] [Abstract][Full Text] [Related]
59. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
